Valuation: Summit Therapeutics Inc.

Market Cap 1.06TCr 1.42TCr 1.24TCr 1.17TCr 2TCr 1,36400Cr 2TCr 14TCr 5.39TCr 69TCr 5.34TCr 5.23TCr 2,23900Cr P/E 2026 *
-14.6x
P/E 2027 * -14.6x
Enterprise Value 1.02TCr 1.36TCr 1.19TCr 1.12TCr 1.91TCr 1,30300Cr 1.91TCr 13TCr 5.16TCr 66TCr 5.11TCr 5TCr 2,14000Cr EV / Sales 2026 *
3,483x
EV / Sales 2027 * 251x
Free-Float
19.11%
Yield 2026 *
-
Yield 2027 * -
15/09 Summit Therapeutics Presents Updated HarmonI Data At WCLC 2026 Demonstrating Consistent Overall Survival Results With Ivonescimab Plus Chemotherapy In Western And Asian Patients CI
15/09 Summit Therapeutics Shares Rise After Partner Akeso's Ivonescimab Phase 3 Lung Cancer Study in China Shows Survival Benefit MT
10/09 Summit Therapeutics Shares Rise After Upgrade From Jefferies MT
09/09 Jefferies Upgrades Summit Therapeutics to Buy From Hold, Adjusts Price Target to $25 From $15 MT
26/08 Exchange-Traded Funds Lower, Equity Futures Mixed Pre-Bell Wednesday Amid Inflation Data Release MT
26/08 US Equity Futures Mostly Flat Pre-Bell as Traders Weigh Inflation Data, Await Nvidia Results MT
26/08 Summit Therapeutics Says Partner's Potential Biliary Tract Cancer Treatment Meets Primary, Secondary Endpoints MT
26/08 Summit Therapeutics Reports Positive Topline Results From Phase III HARMONi-GI1 Study Evaluating Ivonescimab Plus Chemotherapy Compared With Durvalumab Plus Chemotherapy In First-Line Advanced Biliary Tract Cancer CI
25/08 Wall Street Wants Receipts Zonebourse
25/08 Analyst recommendations: AMD, Dynatrace, Elastic, Revolution Medicines… Zonebourse
12/08 Summit Therapeutics Says Its Partner Akeso Gets China Approval for Ivonescimab in Squamous NSCLC MT
12/08 Leerink Partners Upgrades Summit Therapeutics to Market Perform From Underperform, Adjusts PT to $13 From $12 MT
05/08 Summit Therapeutics Expands Ivonescimab Global Development Program With Phase II/III Harmonigu1 Study In First-Line Bladder Cancer CI
1 day-5.32%
1 week-3.70%
Current month+24.08%
1 month+35.96%
3 months+22.91%
6 months+8.96%
Current year-3.37%
1 week 16.64
Extreme 16.64
18.47
1 month 12.22
Extreme 12.22
18.83
Current year 12.07
Extreme 12.07
29.23
1 year 12.07
Extreme 12.07
29.23
3 years 1.64
Extreme 1.64
36.91
5 years 0.66
Extreme 0.66
36.91
10 years 0.66
Extreme 0.66
36.91
Manager TitleAgeSince
Chief Executive Officer 55 25/07/2022
Chief Executive Officer 81 01/04/2020
Director of Finance/CFO 48 02/04/2024
Director TitleAgeSince
Chairman 81 01/02/2020
Director/Board Member 48 01/12/2019
Director/Board Member 55 11/11/2020
Date Insider Type Main position Quantity % Market Cap. Importance
04/06/26 Buy

Chief Executive Officer

1,00,000 0.0129%
04/06/26 Buy

Chief Executive Officer

1,00,000 0.0129%
04/06/26 Buy

Chief Financial Officer

50,000 0.0064%
Change 5-day change 1-year change 3-year change Capi.($)
-5.32%-3.70%-10.53%+808.60% 1.42TCr
+4.98%+11.06%+54.45%+109.45% 7.09TCr
-0.39%+1.66%+38.84%+78.01% 6.25TCr
+5.26%+12.77%+40.29%+26.34% 2.63TCr
+0.83%-6.50%-16.41%+374.14% 2.62TCr
+2.02%+1.31%+1.85%-9.77% 2.41TCr
0.00%+8.03%+25.03%-13.74% 2.07TCr
-2.54%-10.16%+149.64%+313.93% 1.57TCr
-1.95%+1.96%+42.69%+166.02% 1.45TCr
+7.37%+6.53%-2.73%+511.10% 1.41TCr
Average +1.03%+1.68%+32.31%+236.41% 2.89TCr
Weighted average by Cap. +1.72%+2.72%+35.47%+168.18%

Financials

2026 *2027 *
Net sales 29.23L 39.08L 34.07L 32.07L 54.81L 37Cr 54.87L 3.84Cr 1.48Cr 19Cr 1.47Cr 1.44Cr 61Cr 4.17Cr 5.58Cr 4.86Cr 4.58Cr 7.82Cr 534.09Cr 7.83Cr 55Cr 21Cr 272.08Cr 21Cr 20Cr 877.08Cr
Net income -69Cr -92Cr -81Cr -76Cr -129.71Cr -8.86TCr -129.86Cr -909.52Cr -350.44Cr -4.51TCr -347.01Cr -339.69Cr -15TCr -73Cr -98Cr -86Cr -81Cr -137.66Cr -9.4TCr -137.81Cr -965.22Cr -371.9Cr -4.79TCr -368.26Cr -360.5Cr -15TCr
Net Debt -47Cr -63Cr -55Cr -52Cr -88Cr -6.02TCr -88Cr -618.04Cr -238.13Cr -3.07TCr -235.8Cr -230.83Cr -9.88TCr -20Cr -27Cr -23Cr -22Cr -38Cr -2.56TCr -38Cr -263.23Cr -101.42Cr -1.31TCr -100.43Cr -98Cr -4.21TCr
Logo Summit Therapeutics Inc.
Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician, caregiver and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. Its lead development candidate is ivonescimab, a novel, potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. Ivonescimab is being developed by both Akeso and the Company in multiple Phase III clinical trials. It is also developing ivonescimab in non-small cell lung cancer and other solid tumor settings. Ivonescimab is approved in China in combination with chemotherapy for patients with EGFR-mutated non-small cell lung cancer whose tumors have progressed following an EGFR-TKI based on the results of the HARMONi-A clinical trial.
Employees
265
Date Price Change Volume
21/26/21 $16.90 -5.32% 57,67,674
18/26/18 $17.85 +0.73% 1,30,60,581
17/26/17 $17.72 +2.43% 61,34,988
16/26/16 $17.30 -0.57% 60,87,888
15/26/15 $17.40 -5.54% 57,96,861
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
13.35GBP
Average target price
21.57GBP
Spread / Average Target
+61.65%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SMMT Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!